aHUS Research Update: Dec 2020
What's new in atypical HUS Research & Publications? aHUS Alliance Global Action - Keeping you updated with new aHUS research as of December 2020.
AstraZenaca to buy Alexion
Article No. 403 12 December 2020 News has emerged, in the past two hours, that Alexion is to be bought for…
TMA-Semantics are important
Article No. 402 12 December 2020 Just over a year ago aHUS Global Action featured a series of articles "aHUS is…
A day in an aHUS life
Article No. 401 11 December 2020 When it comes to those who have aHUS in their lives , everyone has some…
Withdrawal evidence patients need to know
Article No. 400 5 December 2020 Whilst on the topic of safe withdrawal from eculizumab treatment ( see previous articles 398…
“StopEcu” – the French Study reports
Article No. 399 4 December 2020 Just as the previous blog (No. 398) on the same topic was being written and…
Eculizumab withdrawal risk profiling
Article No. 398 4 December 2020 In its previous article "Dip into ASH 2020" Global Action highlighted research results relating to…
Dip into ASH 2020
Article No. 397 28 November 2020 The second major conference at this time of year with research results which matter…
Atypical HUS: Not Like the Others
Patient involvement needs to be integrated across all areas of research and at early stages of planning clinical trials. When patient engagement is in the atypical HUS arena, what considerations make outreach a bit different for advocacy regarding this ultra rare disease?
- Go to the previous page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- …
- 83
- Go to the next page